Cytokinetics Awaits Amgen's Phase III Plan After Phase II Heart Drug Success

Next steps in the development of heart failure drug omecamtiv mecarbil are unclear following the successful conclusion of a Phase II clinical trial while Cytokinetics Inc. waits to determine with partner Amgen Inc. whether the mid-stage data are sufficient to justify investment in a Phase III program.